Trial Profile
A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 02 Sep 2022 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 16 Aug 2022 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.